HALO Halozyme Therapeutics (HALO) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001159036
Congress · 1Form 144 · 4
Insider buyers, 180 days
0
Funds added, last quarter
384
13F, latest reported quarter
Conversions, 180 days
19
Codes C/M, not in net · $4.8M priced
What the filings say about HALO
Insiders, 180 days
-$29.9M net sold
4 sellers · 57% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 1 sold
Latest: sale, 2026-09-29
Planned sales (Form 144), 90 days
$31.8M
4 notices
Halozyme Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, HALOZYME THERAPEUTICS, INC. insiders sold a net $29.9M of stock across 295 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 174 earlier Form 4 trades (code P or S) here by this insider (174 sales), the last on Oct 7, 2026.
- The trade is 0.6% of the 782,970 shares held after it.
- 1 other insider sold within 30 days.
- 384 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PRESIDENT AND CEO Torley Helen sold about $520.3K of HALO under a 10b5-1 plan on Oct 8, 2026; 1 other insider sold within 30 days and 384 funds added in the latest 13F quarter.Context
- 174 earlier Form 4 trades (code P or S) here by this insider (174 sales), the last on Oct 7, 2026.
- The trade is 0.4% of the 779,880 shares held after it.
- 1 other insider sold within 30 days.
- 384 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PRESIDENT AND CEO Torley Helen sold about $336.5K of HALO under a 10b5-1 plan on Oct 8, 2026; 1 other insider sold within 30 days and 384 funds added in the latest 13F quarter.Context
- 174 earlier Form 4 trades (code P or S) here by this insider (174 sales), the last on Oct 7, 2026.
- The trade is 1.5% of the 767,980 shares held after it.
- 1 other insider sold within 30 days.
- 384 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PRESIDENT AND CEO Torley Helen sold about $1.3M of HALO under a 10b5-1 plan on Oct 8, 2026; 1 other insider sold within 30 days and 384 funds added in the latest 13F quarter.Context
- 174 earlier Form 4 trades (code P or S) here by this insider (174 sales), the last on Oct 7, 2026.
- The trade is 0.0% of the 767,780 shares held after it.
- 1 other insider sold within 30 days.
- 384 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PRESIDENT AND CEO Torley Helen sold about $22.1K of HALO under a 10b5-1 plan on Oct 8, 2026; 1 other insider sold within 30 days and 384 funds added in the latest 13F quarter.Context
- 170 earlier Form 4 trades (code P or S) here by this insider (170 sales), the last on Oct 6, 2026.
- The trade is 1.1% of the 779,180 shares held after it.
- 1 other insider sold within 30 days.
- 384 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PRESIDENT AND CEO Torley Helen sold about $954.9K of HALO under a 10b5-1 plan on Oct 7, 2026; 1 other insider sold within 30 days and 384 funds added in the latest 13F quarter.295 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$29.9M over 180 days
-$22.1M over 90 days
below 91% of Pharma & Biotech
Congress
1 member bought in the last year
the lowest in Pharma & Biotech
Funds
384 funds bought in last quarter
more than 96% of Pharma & Biotech
Revenue
+37.6% year over year
more than 73% of Pharma & Biotech
Margin
22.7% net margin
more than 88% of Pharma & Biotech
Buybacks
$332.7M repurchased, FY to 2026-06-30
more than 84% of Pharma & Biotech
Short interest
13.6% of the float short (float per yahoo 2026-10-26) · 4.5 days to cover · settled 2026-09-30
more than 81% of Pharma & Biotech
What changed in the last 30 days
Oct 12Rep. Gilbert Cisneros sold $1.0K to $15K, disclosed 13 days after the trade
Why it matters
House members report a bracket, not an exact amount, and have 45 days to do it; the trade is weeks old when it becomes public.
Oct 8PRESIDENT AND CEO Torley Helen sold $6.6M under a 10b5-1 plan (12 trades, Oct 6 to Oct 8)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 2Director Posard Matthew L. sold $567.7K under a 10b5-1 plan (Oct 1)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Watch HALO
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+91.4%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns HALO: institutional holders (13F)
13F holdings, latest reported quarter
13,271,095 sh
$1.0B
5,351,312 sh
$418.8M
5,299,008 sh
$414.8M
5,179,434 sh
$405.4M
3,177,997 sh
$248.7M
Congress trades in HALO
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2026-09-29 · disclosed 13 days later
$1,001 - $15,000
Bought 2026-03-09 · disclosed 29 days later
$1,001 - $15,000
Sold 2025-03-24 · disclosed 14 days later
$1,001 - $15,000
Sold 2024-09-09 · disclosed 24 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
HALO planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
MATTHEW POSARD
Filed 2026-09-16
$3.6M
Helen Torley
Filed 2026-08-17
$23.7M
CORTNEY A CAUDILL
Filed 2026-08-11
$4.3M
BERNADETTE CONNAUGHTON
Filed 2026-08-10
$167.7K
MAHESH KRISHNAN
Filed 2026-06-29
$547.5K
HALO mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
The Future Fund Long/Short ETF
$1.5M position · as of 2026-05-31
3.5%
Leadershares Alphafactor Tactical Focused ETF
$2.2M position · as of 2026-07-31
3.4%
Congress Mid Cap Growth Fund
$12.6M position · as of 2026-07-31
3.3%
FundX Future Fund Opportunities ETF
$7.7M position · as of 2026-06-30
3.2%
M3Sixty Income and Opportunity Fund
$532.3K position · as of 2026-05-31
3.2%
First Trust NYSE Arca Biotechnology Index Fund
$87.6M position · as of 2026-06-30
3.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
1 registered trials, 1 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 3
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Helen I Torley
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$23.2M
$39.7M
$3.6M
+58%
+25%
2024
$12.7M
$20.7M
$4.2M
+12%
-7%
2023
$11.8M
-$3.6M
$3.6M
-13%
-6%
2022
$9.7M
$22.8M
$2.4M
+33%
-10%
2021
$7.5M
$6.0M
$2.4M
-6%
+0%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $29.9M sold by insiders over 180 days, 384 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade, $31.8M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
HALO financials
Revenue growth
+37.6%
XBRL, annual
Net margin
22.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.7B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM HALO
| FY Dec 2025 | $1.4B |
| FY Dec 2024 | $1.0B |
| FY Dec 2023 | $829.3M |
| FY Dec 2022 | $660.1M |
| FY Dec 2021 | $443.3M |
| Jun 2026 | $481.0M |
| Mar 2026 | $376.7M |
| Dec 2025 | $451.8M |
| Sep 2025 | $354.3M |
| Jun 2025 | $325.7M |
| Mar 2025 | $264.9M |
| Dec 2024 | $298.0M |
| Sep 2024 | $290.1M |
At each fiscal year end
Single quarter
Net margin, TTM
+24.9%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM HALO
| FY Dec 2025 | +22.7% |
| FY Dec 2024 | +43.7% |
| FY Dec 2023 | +34.0% |
| FY Dec 2022 | +30.6% |
| FY Dec 2021 | +90.8% |
| Jun 2026 | +47.8% |
| Mar 2026 | +39.8% |
| Dec 2025 | -31.3% |
| Sep 2025 | +49.5% |
| Jun 2025 | +50.7% |
| Mar 2025 | +44.6% |
| Dec 2024 | +46.0% |
| Sep 2024 | +47.2% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$806.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM HALO
| FY Dec 2025 | $644.6M |
| FY Dec 2024 | $468.4M |
| FY Dec 2023 | $373.3M |
| FY Dec 2022 | $235.3M |
| FY Dec 2021 | $298.0M |
| Jun 2026 | $236.7M |
| Mar 2026 | $176.3M |
| Dec 2025 | $217.6M |
| Sep 2025 | $175.6M |
| Jun 2025 | $98.1M |
| Mar 2025 | $153.3M |
| Dec 2024 | $175.4M |
| Sep 2024 | $113.9M |
At each fiscal year end
Single quarter
Debt to equity
14.95x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity HALO
| FY Dec 2025 | 43.89x |
| FY Dec 2024 | 4.14x |
| FY Dec 2023 | 17.89x |
| FY Dec 2022 | 8.87x |
| FY Dec 2021 | 4.45x |
| Jun 2026 | 14.95x |
| Mar 2026 | 9.76x |
| Dec 2025 | 43.89x |
| Sep 2025 | 3.00x |
| Jun 2025 | 4.54x |
| Mar 2025 | 3.13x |
| Dec 2024 | 4.14x |
| Sep 2024 | 3.32x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.38x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt HALO
| FY Dec 2025 | 0.30x |
| FY Dec 2024 | 0.32x |
| FY Dec 2023 | 0.26x |
| FY Dec 2022 | 0.16x |
| FY Dec 2021 | 0.34x |
| Jun 2026 | 0.38x |
| Mar 2026 | 0.32x |
| Dec 2025 | 0.30x |
| Sep 2025 | 0.40x |
| Jun 2025 | 0.36x |
| Mar 2025 | 0.33x |
| Dec 2024 | 0.32x |
| Sep 2024 | 0.27x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+173.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity HALO
| FY Dec 2025 | +153.6% |
| FY Dec 2024 | +198.4% |
| FY Dec 2023 | +222.1% |
| FY Dec 2022 | +110.2% |
| FY Dec 2021 | +231.4% |
| Jun 2026 | +173.7% |
| Mar 2026 | +99.4% |
| Dec 2025 | +153.6% |
| Sep 2025 | +124.5% |
| Jun 2025 | +179.1% |
| Mar 2025 | +147.1% |
| Dec 2024 | +198.4% |
| Sep 2024 | +111.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+17.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets HALO
| FY Dec 2025 | +13.8% |
| FY Dec 2024 | +23.4% |
| FY Dec 2023 | +15.8% |
| FY Dec 2022 | +13.7% |
| FY Dec 2021 | +47.8% |
| Jun 2026 | +17.9% |
| Mar 2026 | +14.3% |
| Dec 2025 | +13.8% |
| Sep 2025 | +27.4% |
| Jun 2025 | +27.7% |
| Mar 2025 | +24.0% |
| Dec 2024 | +23.4% |
| Sep 2024 | +19.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+18.6%
operating income after a 29.1% effective tax rate, over long-term 2026-06-30 plus current 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital HALO
| FY Dec 2025 | +14.3% |
| FY Dec 2024 | +27.3% |
| FY Dec 2023 | +18.8% |
| FY Dec 2022 | +14.4% |
| FY Dec 2021 | n/a |
| Jun 2026 | +18.6% |
| Mar 2026 | +15.8% |
| Dec 2025 | +14.3% |
| Sep 2025 | +34.6% |
| Jun 2025 | +32.4% |
| Mar 2025 | +28.8% |
| Dec 2024 | +27.3% |
| Sep 2024 | +23.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+28.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed HALO
| FY Dec 2025 | +22.0% |
| FY Dec 2024 | +31.1% |
| FY Dec 2023 | +20.3% |
| FY Dec 2022 | +19.8% |
| FY Dec 2021 | +48.2% |
| Jun 2026 | +28.8% |
| Mar 2026 | +23.5% |
| Dec 2025 | +22.0% |
| Sep 2025 | +43.5% |
| Jun 2025 | +36.4% |
| Mar 2025 | +31.8% |
| Dec 2024 | +31.1% |
| Sep 2024 | +25.2% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
37.32x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing HALO
| FY Dec 2025 | 26.19x |
| FY Dec 2024 | 13.94x |
| FY Dec 2023 | 17.52x |
| FY Dec 2022 | 39.24x |
| FY Dec 2021 | 14.62x |
| Jun 2026 | 22.82x |
| Mar 2026 | 22.60x |
| Dec 2025 | 26.19x |
| Sep 2025 | 15.44x |
| Jun 2025 | 11.90x |
| Mar 2025 | 16.97x |
| Dec 2024 | 13.94x |
| Sep 2024 | 18.95x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$16.5B
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value HALO
| FY Dec 2025 | $9.9B |
| FY Dec 2024 | $7.5B |
| FY Dec 2023 | $6.3B |
| FY Dec 2022 | $9.0B |
| FY Dec 2021 | $6.4B |
| Jun 2026 | $11.3B |
| Mar 2026 | $9.5B |
| Dec 2025 | $9.9B |
| Sep 2025 | $9.7B |
| Jun 2025 | $7.9B |
| Mar 2025 | $9.2B |
| Dec 2024 | $7.5B |
| Sep 2024 | $8.6B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+5.5%
TTM free cash flow over market value at close 2026-10-26
FCF yield HALO
| FY Dec 2025 | +8.1% |
| FY Dec 2024 | +7.7% |
| FY Dec 2023 | +7.6% |
| FY Dec 2022 | +3.1% |
| FY Dec 2021 | +5.3% |
| Jun 2026 | +8.7% |
| Mar 2026 | +8.8% |
| Dec 2025 | +8.1% |
| Sep 2025 | +7.0% |
| Jun 2025 | +8.4% |
| Mar 2025 | +6.3% |
| Dec 2024 | +7.7% |
| Sep 2024 | +5.4% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing EPS growth -22%, PEG needs growth
PEG, trailing HALO
| FY Dec 2025 | n/a |
| FY Dec 2024 | 0.22x |
| FY Dec 2023 | 0.38x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 0.07x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | 0.27x |
| Jun 2025 | 0.17x |
| Mar 2025 | 0.31x |
| Dec 2024 | 0.22x |
| Sep 2024 | 0.31x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $1.4B | $1.0B | $829.3M | $660.1M |
| Operating income | $469.0M | $551.5M | $337.6M | $267.5M |
| Net income | $316.9M | $444.1M | $281.6M | $202.1M |
| EPS (diluted) | 2.56 | 3.43 | 2.10 | 1.44 |
| Operating cash flow | $651.6M | $479.1M | $388.6M | $240.1M |
| Cash | $133.8M | $115.8M | $118.4M | $234.2M |
| Long-term debt | $2.1B | $1.5B | $1.5B | $1.5B |
| Buybacks | $342.4M | $250.0M | $402.4M | $200.0M |
SEC XBRL, fiscal years, as known on 2026-10-28
HALO Stock Sonar score 6/7 axes
Find similar shapesCompareHALO ranks highest on profitability (85th percentile) and growth (73rd), and lowest on insider conviction (8th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
HALO filings, in plain words
Are Halozyme Therapeutics insiders buying or selling HALO?
In the 180 days to 2026-10-28, Halozyme Therapeutics insiders were net sellers, a net $29.9M across purchases and sales reported on Form 4, by 4 sellers.
Have members of Congress traded HALO?
Yes. In the year to 2026-10-28, 1 House member disclosed buying HALO and 1 House member disclosed selling it; the latest on record is a sale by Gilbert Cisneros dated 2026-09-29.
Are there planned insider sales of HALO?
Yes. 4 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $31.8M of stock; the latest, by MATTHEW POSARD, was filed 2026-09-16.
Read the full summary
In the 180 days to 2026-10-28, Halozyme Therapeutics insiders were net sellers of HALO, a net $29.9M across purchases and sales reported on Form 4 by 4 sellers. 57% of the 67 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. In the year to 2026-10-28, 1 member of Congress disclosed buying HALO and 1 member disclosed selling it; the latest on record is a sale by Gilbert Cisneros dated 2026-09-29. Insiders filed 4 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $31.8M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
